Cutting edge approaches such as NGS are the future of biomarker testing, but require expertise from industry leaders like QIAGEN to develop. QIAGEN’s biomarker assays are designed to ease the challenges faced by those who perform the tests. By engaging with stakeholders, such as laboratorians and oncologists, QIAGEN’s diagnostic assays aim to deliver multiple benefits… Read article →
Cutting edge approaches which use techniques such as liquid biopsy are the future of biomarker testing, but require expertise and leadership to develop. QIAGEN’s companion diagnostic assays are designed to ease the challenges faced by pathologists in labs performing the tests. By engaging with stakeholders, such as laboratorians and oncologists, QIAGEN’s diagnostic assays aim to… Read article →
A recent publication in the Journal of Precision Medicine highlights QIAGEN’s companion diagnostic business development and Modaplex platform. The July 2016 issue of the Journal_of_Precision_Medicine (JPM) features an article by Jessica Johnson called “Companion Diagnostics – a Burgeoning Market” (1). In this article, Johnson provides a brief account of the recent history of companion diagnostics… Read article →
